Crispr Therapeutics Editas Medicine: Better Buy in 2026?
Two top gene-editing names, two very different strategies. This guide breaks down CRISPR Therapeutics and Editas Medi...
This guide weighs the advantages and drawbacks of target date versus lifecycle funds to help you pick the option that best fits your retirement plan.
25,428 articlesTwo top gene-editing names, two very different strategies. This guide breaks down CRISPR Therapeutics and Editas Medi...
River Road Asset Management just added a notable new position in AptarGroup, acquiring 917,670 shares valued at about...
Capital moves matter. Capricorn Investment Group reduced its Navitas Semiconductor stake by about 1.19 million shares...
A celebrity-backed beverage launch sparked a broader lesson in money management. This piece breaks down how holland’s...
Oracle’s 2026 story blends a sharp stock pullback with strong earnings momentum. Learn what’s driving the 18% drop, w...
Salesforce is set to release Q1 results as investors look for evidence that its AI strategy can rekindle growth. A re...
Planning a summer move in Houston? This practical guide shows how to spot bait-and-switch scams, verify movers, and p...
Outdoor gear players are showing renewed momentum as travel and camping trends rebound. This piece analyzes the leade...
In a $520 billion, fragmented remodeling market, larger players use scale and financing access to win more projects, ...
When a senior leader at Black Stone Minerals sells a sizeable block of units, it can ripple through the stock. This a...
Insider moves can spark questions about a regional bank's future. This guide explains what a director selling shares ...
Investors have seen Broadcom swing from a rough start to a strong rally. This guide breaks down whether today is the ...